A broad pipeline of mRNA product candidates in oncology

A diverse early-stage pipeline of differentiated programs

Pipeline & Patients

BioNTech develops a broad product pipeline using different scientific approaches and cutting-edge technology platforms. BioNTech´s clinical pipeline represents a number of industry firsts.

A series of firsts:

BioNTech is the first company worldwide to

  • Implement a medical genomics-driven design and GMP-approved manufacturing process for individual patient-specific therapies
  • Advance an mRNA-based individualized cancer vaccine targeting neoantigens into clinical trials
  • Enter the clinic with an mRNA-based individualized vaccine drawn from a warehouse of mRNAs encoding cancer-selective antigens
  • Test an intravenous formulation of a mRNA vaccine in clinical trials